Drug intelligence / Profile preview

midazolam + ketamine + propofol

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Intravenous
01

Overview

The midazolam + ketamine + propofol combination is a multi-drug sedative regimen used primarily for procedural sedation and analgesia, especially in settings such as colonoscopy and other interventional procedures. Each component contributes distinct pharmacological effects: - **Midazolam** is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, providing anxiolysis, amnesia, and mild sedation. - **Ketamine** is an NMDA receptor antagonist with dissociative anesthetic properties; it provides analgesia and preserves airway reflexes while stimulating the cardiovascular system. - **Propofol** is a short-acting intravenous anesthetic that potentiates GABA-A receptor activity, resulting in hypnosis and deep sedation but can cause hypotension and respiratory depression. When combined, these agents allow for lower individual doses to achieve effective sedation with improved hemodynamic stability and reduced side effects compared to higher doses of single agents. The combination leverages the synergistic actions of each drug—midazolam’s anxiolysis/amnesia, ketamine’s analgesia/cardiovascular support, and propofol’s rapid-onset hypnosis—to provide safe procedural sedation with high patient satisfaction[1][6]. This regimen has been shown to be effective under both anesthetist supervision or trained nurse administration using patient-controlled devices[1].

Other names
midazolam-ketamine-propofol combination
02

Targets

Cyp (Cyclophilin family)GABRR (GABA-A receptor subunit rho)HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on midazolam + ketamine + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on midazolam + ketamine + propofol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call